How can advanced separations, inert hardware, orthogonal methods, and AI solve key challenges in reliable GLP-1 peptide analysis workflows?
|Articles|May 1, 2014
- LCGC North America-05-01-2014
- Volume 32
- Issue 5
Vol 32 No 5 LCGC North America May 2014 Regular Issue PDF
Click the title above to open the LCGC North America May 2014 regular issue, Vol 32 No 5, in an interactive PDF format.
Advertisement
Articles in this issue
over 12 years ago
New Chromatography Columns and Accessories at Pittcon 2014, Part IIover 12 years ago
Joseph Jack Kirkland: HPLC Particle Pioneerover 12 years ago
New Gas Chromatography Products 2014over 12 years ago
Readers' Questions: Calibrationover 12 years ago
Triple-Quadrupole Mass Spectrometers for GC–MSAdvertisement
Related to this article
Liquid chromatography–tandem mass spectrometry (LC–MS/MS) reveals distinct sphingolipid patterns in anorexia and obesity.
Leon Niezen and Gert Desmet discuss uncertainty-driven LC method development, peak overlap, and moving from in silico to real data.
Leon Niezen and Gert Desmet describe how predictive uncertainty can make automated LC method development more reliable.
Liquid chromatography–mass spectrometry (LC–MS) serum profiling ties lysine compounds to lupus kidney disease.
Liquid chromatography-mass spectrometry (LC–MS) growth lifts Waters Q3; MOBILion ion mobility buy expands proteomics.
Liquid chromatography–tandem mass spectrometry (LC–MS/MS) measures galactose-1-phosphate in dried blood spots to monitor galactosemia.
Sam Whitmarsh explores how retention-time models handle interlaboratory data, novel chemotypes, unusual phases and ionisable compounds, and what labs need to do to build useful in-house models.
Advertisement
Advertisement
Trending on LCGC International
1
LCGC Blog: Building a Career Series That Goes Beyond the Surface
2
AI/ML Now: Toxicity Prediction for Unknown LC–HRMS Features Using Machine Learning
3
Industry Roundup: Waters Posts Strong Third Quarter as LC–MS and Chromatography Consumables Drive Growth, Acquires Ion Mobility Pioneer MOBILion
4
From 9000 Clues to a Clinical Test: Mass Spectrometry-Driven Lipidomics for Early Cancer Detection
5